Randomized Trialhigh evidence
Deramiocel heart-derived cellular therapy in advanced Duchenne muscular dystrophy (HOPE-3): a phase 3, randomised, double-blind, placebo-controlled trial.
Lancet (London, England)·July 29, 2026·PMID 42526472
Why it mattersAdvanced DMD lacks disease-modifying therapies that preserve upper limb function, which is critical for quality of life and independence. Deramiocel offers a mutation-agnostic, outpatient-administered option that may fill this gap.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled